CoV-2 S1 (319-537)
HEK293 Cells.
Protein is >90% pure as determined SDS-PAGE.
Description
The HEK293 derived recombinant protein contains the Coronavirus 2019 Spike Glycoprotein S1 Receptor Binding Domain [ RBD ], Wuhan-Hu-1 strain, amino acids 319-537, having a Mw of 26.5kDa.
Cov-2 RBD is fused to His tag at C-terminal
Product Specs
The novel coronavirus (2019-nCoV) responsible for the 2019 outbreak of viral pneumonia was identified in December 2019 in Wuhan, China. This virus, initially found in a seafood market, shares a high genetic similarity with bat coronaviruses, suggesting a possible animal origin.
Genetic analysis reveals that 2019-nCoV shares 87% identity with bat SARS-related coronaviruses, specifically the SARS-CoV-2 strain. The virus's receptor-binding domain (RBD) structure closely resembles that of SARS-CoV, enabling it to potentially bind to the human ACE2 receptor, a key protein involved in regulating blood pressure.
While bats are suspected to be the natural reservoir of 2019-nCoV, an intermediate animal host, potentially from the seafood market, is thought to have facilitated transmission to humans. Notably, research suggests that 2019-nCoV's spike glycoprotein, crucial for host cell entry, might be a product of recombination between a bat coronavirus and an as-yet-unidentified coronavirus.
This recombinant protein, derived from HEK293 cells, corresponds to the Receptor Binding Domain (RBD) of the SARS-CoV-2 Spike Glycoprotein S1 (Wuhan-Hu-1 strain, amino acids 319-537). This protein, with a molecular weight of 26.5kDa, includes a C-terminal His tag for purification and detection.
The product is lyophilized (freeze-dried) from a solution containing PBS at pH 7.4, 10% trehalose, and has been sterile filtered through a 0.2µm filter.
For optimal reconstitution, dissolve the lyophilized CoV-2 S1 protein in sterile, ultrapure water (18 MΩ·cm) to a concentration of 0.5 mg/ml. A minimum concentration of 0.1 mg/ml is acceptable. The reconstituted protein can be further diluted in other aqueous solutions as needed.
While the lyophilized Cov-2 RBD protein remains stable at room temperature for up to three weeks, it is recommended to store it desiccated at a temperature below -18°C. After reconstitution, the CoV2 RBD protein can be stored at 4°C for 2-7 days. For long-term storage, freeze the reconstituted protein below -18°C. It is advisable to add a carrier protein (0.1% HSA or BSA) to enhance stability during storage. Avoid repeated freeze-thaw cycles.
The purity of this protein is determined to be greater than 90% using SDS-PAGE analysis.
HEK293 Cells.
Purified by Metal-Afinity chromatographic technique.
Product Science Overview
The Coronavirus 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a profound impact on global health. A critical component of the virus is the spike (S) glycoprotein, which plays a pivotal role in the virus’s ability to infect host cells. The spike glycoprotein is composed of two subunits, S1 and S2, with the S1 subunit containing the receptor-binding domain (RBD) that is essential for the virus to attach to and enter host cells .
The spike glycoprotein is a large type I transmembrane protein that protrudes from the surface of the virus. The S1 subunit, specifically the receptor-binding domain (RBD), spans amino acids 319 to 537. This domain is responsible for binding to the angiotensin-converting enzyme 2 (ACE2) receptor on the surface of host cells . The interaction between the RBD and ACE2 is the initial step in the viral entry process, facilitating the fusion of the viral and cellular membranes .
Recombinant production of the SARS-CoV-2 spike glycoprotein S1 RBD involves expressing the protein in a suitable host system, such as mammalian cells, insect cells, or yeast. This allows for the production of large quantities of the protein for research and therapeutic purposes. The recombinant S1 RBD can be used in various applications, including vaccine development, diagnostic assays, and therapeutic interventions .
The S1 RBD is a major target for neutralizing antibodies, making it a key focus for vaccine development. Vaccines that elicit an immune response against the RBD can potentially block the virus from binding to the ACE2 receptor, thereby preventing infection. Several COVID-19 vaccines, including mRNA-based vaccines, have been designed to induce an immune response against the spike glycoprotein, particularly the RBD .
In addition to its role in vaccine development, the recombinant S1 RBD is used in therapeutic and diagnostic applications. For instance, it can be employed in serological assays to detect antibodies against SARS-CoV-2 in patient samples. Furthermore, the RBD can be used to screen for potential antiviral compounds that inhibit the interaction between the virus and the ACE2 receptor .
